Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
NEW YORK, May 16, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of New York on behalf of investors who purchased Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies") (NASDAQ:ITCI) securities between August 12, 2014 and April 28, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/intra-cellular-therapies-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
If you suffered a loss in Intra-Cellular Therapies you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/intra-cellular-therapies-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
